Novo Nordisk Fends Off Cyber Pirates and Copycats as Shares Rally

Novo Nordisk rallies 12% after cyberattack and extortion demands; stock supported by $15B buyback, court injunctions against Wegovy copycats, and UK approval of oral GLP-1 pill.

The Danish pharmaceutical giant has spent the past week navigating a peculiar dichotomy: fending off a sophisticated cyber-extortion attempt while simultaneously winning legal battles against producers of unlicensed Wegovy copies. The result has been a sharp rebound in the stock, which has climbed roughly 12% over the past seven trading sessions to €42.09 — a marked recovery from the 52-week low of €30.25, though still about 27% below the level of a year ago.

Two separate hacker groups — FulcrumSec and TheUSERS007 — infiltrated Novo Nordisk’s network over a period of more than two months. FulcrumSec gained initial entry through a GitHub access token discovered in March, then cloned internal repositories and extracted further credentials. TheUSERS007 independently breached the same system. Together, they stole over 700,000 files encompassing source code, clinical trial data, details on marketed and pipeline drugs (including Amycretin and CagriSema), internal AI models, and pseudonymized data from roughly 11,500 study participants. The groups demanded €25 million and €50 million respectively as ransom; Novo Nordisk refused to pay. After the extortion failed, FulcrumSec began offering the stolen data for sale on the dark web.

The company has since brought in external cybersecurity experts, notified relevant authorities, and temporarily shut down some internal IT systems. It insists core operations remain unaffected, and that the clinical data is pseudonymized without direct patient identifiers. Still, the incident exposes Novo Nordisk to potential regulatory fines, formal investigations, and costly remediation — a backdrop that makes the stock’s recent rally all the more striking.

That rally has been reinforced by a formidable buyback programme. The current tranche, launched in early February 2026, authorises up to 15 billion Danish kroner in share repurchases over twelve months. In the week ending 19 June alone, the company bought roughly 1.075 million B-shares, bringing the total since programme inception to about 21 million shares worth around 5.6 billion kroner.

Meanwhile, legal and regulatory developments have provided additional tailwinds. A South African court last week issued a preliminary injunction barring local manufacturer iDexis from producing illegal copies of Wegovy. In parallel, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral formulation of Wegovy as the first GLP-1 pill for weight loss in Britain — a significant expansion of the product’s addressable market. The oral Wegovy pill also posted first-quarter sales of 2.3 billion Danish kroner, nearly double analysts’ expectations.

Novo Nordisk has also secured a deal with the telemedicine platform Hims & Hers, which agreed to stop marketing copycat products and instead sell the original Wegovy. The US Food and Drug Administration (FDA) is weighing even stricter measures: it has proposed removing compounded GLP-1 injectables from a key pharmacy exemption list, with a public comment period ending on 29 June 2026. If enacted, a ban would severely curtail the mass production of unregulated copies in America.

Yet fundamental headwinds remain intense. Revenue and operating profit are expected to decline by four to twelve percent in 2026, driven largely by pricing pressure in the United States. Lower Medicaid reimbursements and new pricing agreements are compressing margins, while rival Eli Lilly secured FDA approval for its own oral obesity drug Foundayo in April, ending Novo Nordisk’s monopoly in the pill segment. The pipeline has also suffered a setback: CagriSema failed to deliver clear superiority data in recent trials.

The technical picture is mixed. The stock’s relative strength index sits at nearly 71, signalling an overbought condition. The shares have only just reclaimed the 200-day moving average — by a slim 2.32% margin. Maintaining that level will be critical for the near-term trend.

Two catalysts will dominate the weeks ahead. First, the outcome of the FDA’s comment period on compounded copies; a strong ban could propel the stock, while a weak ruling might trigger a reversal. Second, Phase III data for Amycretin — a dual-hormone agonist — are expected soon, and positive results would reinforce the long-term growth narrative. Beyond that, the next quarterly earnings report on 5 August will test whether Novo Nordisk can reaffirm its full-year guidance amid the cyberattack fallout and persistent pricing headwinds.